/Zoetis%20Inc%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)
Valued at a market capitalization of $50.8 billion, Parsippany, New Jersey-based Zoetis Inc. (ZTS) is a leader in the animal health space and is engaged in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions in the United States and internationally.
ZTS is expected to release its Q1 2026 earnings on Thursday, May 7, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.61 on a diluted basis, up 8.8% from $1.48 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.